Latest for Nocion

Highlight

FierceBiotech: COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread

40% of patients who recover from COVID-19 in hospital get sent home with a postviral cough that lasts three to eight weeks. Containing those coughs, or stopping them altogether, could play a role in curbing the spread of the virus.

Highlight

Endpoints News: Nocion raises $62M for different approach to chronic cough than Merck, GSK

In the middle of 2023, Richard Batycky told a couple of his fellow executives at Nocion Therapeutics to consider looking for roles elsewhere. He...

Highlight

FierceBiotech: Nocion Therapeutics named to Fierce 15

While whole shoals of biotechs are clustered around single cancer targets, Nocion is away from the pack working on better ways to treat conditions...

Highlight

Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation

Today, Canaan proudly introduces Nocion Therapeutics, a Series A neurogenic inflammation and analgesic company discovering and developing novel...

Activity

Fierce Biotech: Nocion grabs new CMO as it kicks off COVID-19 cough study

Activity

Business Insider: Meet the 21 biotech startups that top VCs say are poised to take off in the next 12 months

Activity

FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain

Activity

Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up

Activity